Skip to content
TrialScanner

NCT06568692

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Phase 2TerminatedPCSALead

Registry record

Lead sponsor
Processa Pharmaceuticals
Conditions
Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer
Primary completion
Jul 29, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT06568692 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT06568692: A Phase 2 Study of PCS6422... | TrialScanner